Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)" to support collaborative translational research projects aimed at bridging basic biological discoveries with clinical applications to enhance health outcomes. This program encourages partnerships between NIH intramural and extramural investigators, requiring that applications include at least one intramural scientist as a co-Principal Investigator and that a significant portion of the research is conducted at the NIH Clinical Center. The maximum funding amount is $500,000 in direct costs annually for up to four years, with applications due between January 5, 2026, and March 6, 2027. Interested applicants can reach out to David J. Eckstein at ClinicalCtrPartner@mail.nih.gov for further information.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.